TB-500 Legal Status, FDA 503A Category, and Compounding Access

Where access could be headed in 2026 — and why that is momentum, not a decision

The TB-500 legal status is, right now, under active FDA review — and access may expand in 2026. That forward read rests on one verifiable fact: TB-500 (free base) and TB-500 acetate are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as bulk drug substances being considered for inclusion on the 503A Bulks List ^[14]. The same agenda lists BPC-157, KPV, and MOTs-C ^[14]. A substance moving onto a PCAC agenda is a substance FDA is actively evaluating, in public, on the record.

Read the momentum honestly, though. A PCAC meeting is a scheduled evaluation and discussion — it is advisory. It is not a listing decision, not a reclassification, and not a change in the current status ^[14][15]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC; being discussed is a step in evaluation, not an outcome ^[15]. The honest forward statement is under active review, may expand — never reclassified and never with a date attached to a predicted result ^[15]. We do not repeat the unconfirmed reports of an early-2026 reclassification or an April-2026 removal; those could not be verified from an authoritative FDA source ^[15].

Is TB-500 FDA approved? The present-tense fact

No. TB-500 is not an FDA-approved drug, and it currently sits in 503A Category 2. FDA lists the entry as Thymosin beta-4, fragment (LKKTETQ), also known as TB-500 and identified it as a bulk drug substance that may present significant safety risks, placing it in Category 2 for 503A compounding effective with FDA's September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information ^[14]. FDA's own list entry establishes the relationship: TB-500 is the LKKTETQ fragment associated with thymosin beta-4 ^[14].

What Category 2 means in practice is specific. Per FDA's interim policy, Category 2 bulk substances were nominated with enough information to evaluate but were identified as raising significant safety risks, and they are not covered by the enforcement-discretion policy that applies to Category 1 — FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[15]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated ^[15]. So as the record stands: not an approved drug, a Category 2 bulk substance, and not within FDA's 503A enforcement-discretion policy ^[14][15].

How legally compounded peptide access works

Drug compounding in the U.S. runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that may compound larger batches under cGMP-style oversight and inspection ^[15]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[15].

The lawful access pathway, in general terms, runs in one direction: a patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate; if appropriate and lawful, the prescriber issues a valid, patient-specific prescription; that prescription is then dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[16]. Telehealth is one front-end channel for the prescriber-evaluation step — a route to a licensed-prescriber consultation, not a separate legal status, and it does not expand which substances may be compounded ^[16].

Here is the binding caveat for TB-500 specifically. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules; an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[16]. TB-500 is a Category 2 substance, so while that standing holds it is not within routine 503A compounding eligibility ^[14][16]. This page names no specific pharmacy, clinic, telehealth provider, or vendor, gives no dosing or administration instructions, and describes no way to obtain a restricted substance outside the lawful framework. It is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance.

The rest of the record: WADA and research/veterinary standing

Beyond the FDA compounding question, TB-500 carries an anti-doping prohibition. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited peptide, growth-factor and tissue-repair categories, banned in and out of competition for the relevant classes, and are detected by LC-MS anti-doping assays in equine and human matrices ^[12]. TB-500 has also been encountered as a designer drug in racehorses, which prompted the equine and human detection methods ^[12].

The finished-drug question and the bulk-substance question are separate. FDA approval of a finished drug — a New Drug Application or Biologics License Application — is a different determination from whether a bulk substance may be used in compounding, and TB-500 is neither an approved finished drug nor currently eligible for routine 503A compounding ^[15]. Outside the U.S., it is classified as a prescription medicine in some jurisdictions. Read as a whole, the record is: research and veterinary-context substance, no approved human indication, Category 2 for 503A compounding, WADA-prohibited, and individually under active PCAC review for July 2026 ^[12][14].

Is TB-500 legal?

TB-500 is not an FDA-approved drug and is handled as a research / veterinary-context substance in the U.S.; it is prohibited in sport by WADA and classified as a prescription medicine in some jurisdictions ^[12]. For compounding, FDA placed it in 503A Category 2 (significant-safety-risk) effective September 29, 2023, so it is not within FDA's enforcement-discretion policy for routine 503A compounding ^[14]. This is general regulatory information, not legal advice.

Can you get TB-500 from a compounding pharmacy?

Legally compounded access requires a licensed-prescriber evaluation and a valid patient-specific prescription, filled by a 503A pharmacy or 503B outsourcing facility ^[16]. But a compounder may use an ingredient only if it is eligible under the bulk-substance rules, and a Category 2 substance like TB-500 is not eligible for routine 503A compounding while that status stands ^[14][16]. This page names no pharmacy or provider.

What is the FDA 503A status of TB-500?

FDA lists Thymosin beta-4, fragment (LKKTETQ), also known as TB-500 and placed it in 503A Category 2 — a bulk substance identified as possibly presenting significant safety risks — effective with the September 29, 2023 update, citing immunogenicity and a lack of important safety information ^[14]. TB-500 (free base) and TB-500 acetate are on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A Bulks List, which is a scheduled discussion, not a decision ^[14].